Optimal Design of Drug-Drug Interaction Studies for the GLP-1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap

被引：0
|
作者：
Weber, Elijah [1 ]
Trivedi, Ashit [2 ]
Barbour, April M. [1 ]
机构：
[1] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Gaithersburg, MD USA
[2] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci, R&D, Waltham, MA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2025年
关键词：
clinical pharmacology study design; drug-drug interaction; gastric-emptying delay; GLP-1; RA; oral contraceptive;
D O I：
10.1002/jcph.70020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 35 条
  • [21] A Hydrogel-Microsphere Drug Delivery System that Supports Once-Monthly Administration of a GLP-1 Receptor Agonist
    Schneider, Eric L.
    Hearn, Brian R.
    Pfaff, Samuel J.
    Reid, Ralph
    Parkes, David G.
    Vrang, Niels
    Ashley, Gary W.
    Santi, Daniel V.
    DIABETES, 2017, 66 : LB35 - LB35
  • [22] Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
    Pechenov, Sergei
    Revell, Jefferson
    Will, Sarah
    Naylor, Jacqueline
    Tyagi, Puneet
    Patel, Chandresh
    Liang, Lihuan
    Tseng, Leo
    Huang, Yue
    Rosenbaum, Anton, I
    Balic, Kemal
    Konkar, Anish
    Grimsby, Joseph
    Subramony, J. Anand
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
    Sergei Pechenov
    Jefferson Revell
    Sarah Will
    Jacqueline Naylor
    Puneet Tyagi
    Chandresh Patel
    Lihuan Liang
    Leo Tseng
    Yue Huang
    Anton I. Rosenbaum
    Kemal Balic
    Anish Konkar
    Joseph Grimsby
    J. Anand Subramony
    Scientific Reports, 11
  • [24] Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
    Pechenov, Sergei
    Bhattacharjee, Himanshu
    Yin, Daniel
    Mittal, Sachin
    Subramony, J. Anand
    ADVANCED DRUG DELIVERY REVIEWS, 2017, 112 : 106 - 122
  • [25] Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel D-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide)
    Subramanian, Raju
    Zhu, Xiaochun
    Kerr, Savannah J.
    Esmay, Joel D.
    Louie, Steven W.
    Edson, Katheryne Z.
    Walter, Sarah
    Fitzsimmons, Michael
    Wagner, Mylo
    Soto, Marcus
    Pham, Roger
    Wilson, Sarah F.
    Skiles, Gary L.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (08) : 1319 - 1331
  • [26] Food and Drug Administration Adverse Event Reports of Diabetic Retinopathy, Macular Edema and Blurred Vision Associated with GLP-1 Receptor Agonist Use
    Xiao, Grace
    Li, Albert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [27] Agonist efficacy and the behavioral effects of dopamine D-1 receptor ligands: Drug interaction studies in squirrel monkeys
    Bergman, J
    Spealman, RD
    Madras, BK
    RosenzweigLipson, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 276 (03): : 942 - 950
  • [28] In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450 enzyme identification, inhibition, and induction studies
    Li, Yan
    Zhou, Diansong
    Ferguson, Stephen S.
    Dorff, Peter
    Simpson, Thomas R.
    Grimm, Scott W.
    XENOBIOTICA, 2010, 40 (11) : 721 - 729
  • [29] Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
    Rosenstock, Julio
    Buse, John B.
    Azeem, Rehan
    Prabhakar, Prakash
    Kjems, Lise
    Huang, Holly
    Baron, Michelle A.
    DIABETES CARE, 2018, 41 (02) : 333 - 340
  • [30] Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy
    Nirogi, Ramakrishna
    Bhyrapuneni, Gopinadh
    Muddana, Nageswara Rao
    Manoharan, Arunkumar
    Shinde, Anil K.
    Mohammed, Abdul Rasheed
    Padala, Nagasurya Prakash
    Ajjala, Devender Reddy
    Subramanian, Ramkumar
    Palacharla, Veera Raghava Chowdary
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 152 : 105425
1234